Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Taxoids

abstract

  • Docetaxel 60 mg/m(2) and vinorelbine 45 mg/m(2), both given every 2 weeks, is a highly active combination for the treatment of advanced NSCLC. Filgrastim largely obviates neutropenic fever and allows for the single-agent dose-intensity of both drugs to be delivered. The occurrence of certain late toxicities can limit use in some cases and suggests that the combination could also be beneficial in settings requiring briefer, fixed periods of treatment, such as in induction or postoperative therapy.

publication date

  • March 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10715307

Additional Document Info

start page

  • 1346

end page

  • 50

volume

  • 18

number

  • 6